Exactech Goes Private in $625M Deal With TPG Capital Post author:Sam Post published:October 22, 2017 Post category:BioPharma TPG Capital has acquired all the outstanding shares of Exactech common stock for $42 per share. Source: BioSpace You Might Also Like Symcel: Calorimetry-Based 3D Phenotype Assays: A Necessity For Drug Discovery And Personalized Medicine June 18, 2017 What Biogen CFO's Departure Means for Company's M&A Strategy June 14, 2017 Lonza Group Unveils Agendia BV For 3rd Annual Global Endotoxin Testing Summit April 20, 2017
Symcel: Calorimetry-Based 3D Phenotype Assays: A Necessity For Drug Discovery And Personalized Medicine June 18, 2017